ODAC Backs Random Sample Audits Of Progression Events
Executive Summary
FDA’s Oncologic Drugs Advisory Committee supports easing the current requirement for blinded, independent central review of 100% of patient scans in studies using progression-free survival as the primary endpoint. However, committee members say FDA needs the flexibility to require full case audits in certain circumstances, depending upon tumor type and study size.
You may also be interested in...
The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival
Submitting an NDA based on progression-free survival when other drugs for the indication have been approved on the basis of overall survival benefits is a risky proposition, but GlaxoSmithKline was confident the magnitude of Mekinist and Tafinlar’s PFS effect in metastatic melanoma would make the findings clinically relevant.
FDA Oncology Panel To Weigh Independent Review Of PFS Event Subset
The Oncologic Drugs Advisory Committee’s July 24 meeting to discuss the merits of independent radiological review of progression assessments in a pre-specified subgroup of patients, instead of 100% of all assessments, comes three years after the agency signaled it was open to considering such an approach.
Afinitor In Pancreatic Tumors: ODAC Sees Consistent Efficacy, But Favors Limits On Use
The consistency of the progression-free survival benefit with Novartis’ Afinitor (everolimus) led FDA’s Oncologic Drugs Advisory Committee to support the drug’s approval for treatment of advanced pancreatic neuroendocrine tumors (PNET) despite questions about the statistical treatment of data in the pivotal study.